Andon Therapeutics Raises Over 400 Million Yuan in Series C Funding to Accelerate Phase III Clinical Trials for Revolutionary Pan-Anemia Drug
Focused on R&D of novel drugs for kidney diseases, pan-anemia conditions, and cancer.
@gaorong
创造美好生活
Focused on R&D of novel drugs for kidney diseases, pan-anemia conditions, and cancer.
"The foundation of quality healthcare."
Models are thinking agents.
Chinese gene therapies have a real shot at genuine innovation — even leapfrogging the competition.
"AI is the biggest variable in the future."
MAI Agent has helped some clients increase sales by over 40%.
The largest single financing round in China's AI application sector so far in 2025.
Back to fundamentals, building differentiation.
"Help 100 robotics brands achieve one-billion-yuan sales within three years."
Banyan light graces the golden hour; the full moon meets an old friend.